Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer

Medical Oncology

Volumn 32, Issue 1, 2015, Pages 1-6

  Cai, Yunlang ^a   Wang, Jingmei ^b   Zhang, Lin ^a   Wu, Di ^a   Yu, Dandan ^a   Tian, Xiaoqiang ^c   Liu, Jun ^a   Jiang, Xinru ^a   Shen, Yang ^a   Zhang, Lihua ^a   Ren, Mulan ^a   Huang, Peilin ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^c Nanjing Second Hospital   (China)

Author keywords

Clinicopathological factors; Fatty acid synthase; HER2; Ovarian cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FATTY ACID SYNTHASE; ERBB2 PROTEIN, HUMAN; FASN PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; CYTOPLASM; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARIAN TISSUE; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; TISSUE MICROARRAY; AGED; BIOSYNTHESIS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION;

ADULT; AGED; BIOMARKERS, TUMOR; FATTY ACID SYNTHASE, TYPE I; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTOR CROSS-TALK; RECEPTOR, ERBB-2; TISSUE ARRAY ANALYSIS;

EID: 84938918739     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0391-z     Document Type: Article

References (21)

1. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7:763–77.
2. Li N, Bu X, Tian X, Wu P, Yang L, Huang P. Fatty acid synthase regulates proliferation and migration of colorectal cancer cells via HER2-PI3K/Akt signaling pathway. Nutr Cancer. 2012;64:864–70.
3. Rahman MT, Nakayama K, Rahman M, Katagiri H, Katagiri A, Ishibashi T, et al. Fatty acid synthase expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas. Br J Cancer. 2012;107:300–7.
4. Hung MC, Lau YK. Basic science of HER-2/neu: a review. Semin Oncol. 1999;26:51–9.
5. Li N, Lu H, Chen C, Bu X, Huang P. Loss of fatty acid synthase inhibits the “HER2-PI3K/Akt axis” activity and malignant phenotype of Caco-2 cells. Lipids Health Dis. 2013;1:83.
6. Grunt TW, Wagner R, Grusch M, Berger W, Singer CF, Marian B, et al. Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochem Biophys Res Commun. 2013;385:454–9.
7. Malthièry Y, Savagner F. Energy metabolism of the cancer cell: example of mitochondria-rich endocrine tumors. Ann Endocrinol (Paris). 2006;67:205–13.
8. Piyathilake CJ, Frost AR, Manne U, Bell WC, Weiss H, Heimburger DC, et al. The expression of fatty acid synthase (FASE) is an earlyevent in the development and progression of squamous cell carcinoma of the lung. Hum Pathol. 2000;31:1068–73.
9. Ogino S, Nosho K, Meyerhardt JA, Kirkner GJ, Chan AT, Kawasaki T, et al. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol. 2008;26:5713–20.
10. Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, et al. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res. 2003;1:707–15.
11. Pizer ES, Thupari J, Han WF, Pinn ML, Chrest FJ, Frehywot GL, et al. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res. 2000;60:213–8.
12. Gansler TS, Hardman W 3rd, Hunt DA, et al. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol. 1997;28:686–92.
13. Verri E, Guglielmini P, Puntoni M, Perdelli L, Papadia A, Lorenzi P, et al. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. Oncology. 2005;68:154–61.
14. Tanabe H, Nishii H, Sakata A, Suzuki K, Mori Y, Shinozaki H, et al. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma. Gynecol Oncol. 2005;94:735–9.
15. Mano MS, Awada A, Di Leo A, Durbecq V, Paesmans M, Cardoso F, et al. Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma. Gynecol Oncol. 2004;92:887–95.
16. Riener EK, Arnold N, Kommoss F, Lauinger S, Pfisterer J. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study. Gynecol Oncol. 2004;95:89–94.
17. Hogdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, et al. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer. 2003;98:66–73.
18. Wang Y, Kristensen GB, Helland A, Nesland JM, Børresen-Dale AL, Holm R. Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas. Am J Clin Pathol. 2005;124:392–401.
19. Camilleri-Broet S, Hardy-Bessard AC, Le Tourneau A, Paraiso D, Levrel O, Leduc B, et al. HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Ann Oncol. 2004;15:104–12.
20. Vazquez-Martin A, Colomer R, Brunet J, Lupu R, Menendez JA. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Prolif. 2008;41:59–85.
21. Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R, et al. Inhibition of fatty acid synthase (FAS) suppresses Her2/neu (ErbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci USA. 2004;101:10715–20.